Frontiers in Immunology (Aug 2021)

p16INK4a Regulates Cellular Senescence in PD-1-Expressing Human T Cells

  • Valérie Janelle,
  • Mathieu Neault,
  • Marie-Ève Lebel,
  • Dave Maurice De Sousa,
  • Dave Maurice De Sousa,
  • Salix Boulet,
  • Ludovic Durrieu,
  • Cédric Carli,
  • Chloé Muzac,
  • Sébastien Lemieux,
  • Sébastien Lemieux,
  • Nathalie Labrecque,
  • Nathalie Labrecque,
  • Nathalie Labrecque,
  • Heather J. Melichar,
  • Heather J. Melichar,
  • Frédérick A. Mallette,
  • Frédérick A. Mallette,
  • Frédérick A. Mallette,
  • Jean-Sébastien Delisle,
  • Jean-Sébastien Delisle,
  • Jean-Sébastien Delisle

DOI
https://doi.org/10.3389/fimmu.2021.698565
Journal volume & issue
Vol. 12

Abstract

Read online

T-cell dysfunction arising upon repeated antigen exposure prevents effective immunity and immunotherapy. Using various clinically and physiologically relevant systems, we show that a prominent feature of PD-1-expressing exhausted T cells is the development of cellular senescence features both in vivo and ex vivo. This is associated with p16INK4a expression and an impaired cell cycle G1 to S-phase transition in repeatedly stimulated T cells. We show that these T cells accumulate DNA damage and activate the p38MAPK signaling pathway, which preferentially leads to p16INK4a upregulation. However, in highly dysfunctional T cells, p38MAPK inhibition does not restore functionality despite attenuating senescence features. In contrast, p16INK4a targeting can improve T-cell functionality in exhausted CAR T cells. Collectively, this work provides insights into the development of T-cell dysfunction and identifies T-cell senescence as a potential target in immunotherapy.

Keywords